Results 171 to 180 of about 162,899 (289)

Validation of the French Translation of the Movement Disorder Society Non‐Motor Symptoms Scale (MDS‐NMS) in Parkinson's Disease

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Clément Desjardins   +283 more
wiley   +1 more source

Types of Pain in Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background Pain affects up to 87% of people with multiple system atrophy (MSA), but it remains unclear which types of pain contribute most to the overall burden. Objective To estimate the frequency of different types of pain in MSA individuals.
Nicole Campese   +19 more
wiley   +1 more source

Efficacy of a K+ Channel Agonist, XEN1101, For Preserving Contractility in Mouse Models of Hypokalemic Periodic Paralysis

open access: yesMuscle &Nerve, EarlyView.
Pretreatment with an agonist of Kv7 potassium channels (XEN1101) protects the soleus muscle from a loss of force during a 2 mM K+ challenge, in a mouse model of hypokalemic periodic paralysis. ABSTRACT Introduction/Aims Effective management remains lacking for recurrent episodes of acute weakness in hypokalemic periodic paralysis (HypoPP).
Viktor Chanchykov   +4 more
wiley   +1 more source

Perioperative Blood Pressure Optimization to Improve Outcomes in Orthopedic Patients: A Clinical Review. [PDF]

open access: yesTher Clin Risk Manag
Yang YF   +7 more
europepmc   +1 more source

Effects of protease inhibitors in experimental septic shock [PDF]

open access: yes, 1992
Fink, Edwin   +3 more
core  

Supplementary parenteral arginine corrects hypoargininaemia and rebalances plasma amino acid profiles in very preterm infants receiving parenteral nutrition: A prospective study

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background Plasma amino acid (AA) profiles in parenteral nutrition (PN)–dependent very preterm infants (VPIs) consistently show overprovision of essential AA (EAA) and arginine deficiency. This may have implications for growth and immune/inflammatory responses.
Frances Callaghan   +6 more
wiley   +1 more source

Validation of the German Version of the Movement Disorder Society Non‐Motor Scale (MDS‐NMS)

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Jonas Bendig   +20 more
wiley   +1 more source

Weekly Subcutaneous VK2735, a GIP/GLP‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week VENTURE Study

open access: yesObesity, EarlyView.
Four doses of VK2735 and a placebo group were included in the VENTURE study. Adults who were overweight or had obesity had significant weight loss when taking any dose of VK2735 for 13 weeks. More people lost at least 10% of their body weight as the dose increased.
Harold E. Bays   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy